Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Gross Margin (2016 - 2025)

Standard Biotools (LAB) has disclosed Gross Margin for 16 consecutive years, with 77.57% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin rose 59572.0% to 77.57% in Q3 2025 year-over-year; TTM through Sep 2025 was 37.82%, a 3057.0% decrease, with the full-year FY2024 number at 48.31%, up 86.0% from a year prior.
  • Gross Margin was 77.57% for Q3 2025 at Standard Biotools, down from 48.84% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 166.4% in Q3 2021 to a low of 673.29% in Q3 2024.
  • A 5-year average of 9.01% and a median of 48.39% in 2025 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: tumbled -71748bps in 2024, then surged 59572bps in 2025.
  • Standard Biotools' Gross Margin stood at 25.05% in 2021, then soared by 265bps to 41.33% in 2022, then grew by 15bps to 47.39% in 2023, then tumbled by -36bps to 30.54% in 2024, then tumbled by -354bps to 77.57% in 2025.
  • Per Business Quant, the three most recent readings for LAB's Gross Margin are 77.57% (Q3 2025), 48.84% (Q2 2025), and 48.39% (Q1 2025).